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ABSTRACT
The RET proto-oncogene is expressed in the developing kidney and enteric nervous system
during vertebrate embryogenesis. It has two major splicing variants; RET9 and RET51. The
expression pattern of the two variants appears to vary among the developing organisms.
RET9 plays a major role in development of kidney and excretory system whereas the role of
RET 51 seems to be of maintenance of these systems after development. The protein RET is
a transmembrane receptor which expresses itself in the cell surface and initiates the signal
transduction pathways for cellular differentiation and proliferation of the cell. The different
expression patterns shown by RET 9 and RET51 isoforms and the work of other researchers
indicating that different RET splice variants result in different phenotype when expressed
independently, are demonstrations of the importance of these splice variations in RET
functioning. In order to expand our understanding on the mechanism of RET splicing, the 3'
end of the RET 9 isoform was isolated and a new construct was created that contained the
exons and introns involved in the RET9 and RET51 splice variations. This region was
placed into a mammalian expression vector in both orientations and the ability to measure
changes in splicing with these constructs was measured. As a sequential step, in this study
two different constructs of a specific region of RET were designed and analyzed using RTPCR and Q-PCR to demonstrate the mechanism of splicing. These constructs are planned to
be further used as a model for the study of conditions that lead to splicing of Human RET
proto-oncogene. While no differences were seen in initial studies, the development of the
constructs and the evaluation of these constructs will provide an opportunity to study this
important splicing event in more detail.
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INTRODUCTION
RET, an abbreviation for “Rearranged during Transfection”, was first identified by
Takahashi et al. (1985). The transfection of NIH3T3 cells with human lymphoma DNA
resulted in the activation of a novel transforming gene. This biologically active gene was
generated by the recombination of two fragments of distantly located normal cell DNA1.
Since then several research works have been undertaken involving the RET gene. These
findings have shown that the protein RET is a cell surface receptor and is expressed in cell
lineages derived from the neural crest. It plays an important role in regulation of cell
proliferation, migration, differentiation and survival during embryogenesis. This protein
consists of three extracellular and an intracellular domain. The extracellular region consists
of four cadherin-like repeats, a calcium-binding site, and a cysteine-rich domain while the
intracellular portion contains a typical bipartite tyrosine kinase domain.2
The receptor RET is activated by one of the 4 ligands of GDNF family; GDNF, neutrin,
artemin and persephin. The activation of RET is mediated by one of the four coreceptors
named as GDNF family coreceptors (GFRal-4). The interaction of RET with GDNF and
GFRal occurs through its cadherin domain (CLD4 and CRD).9 RET activation occurs by
initial binding of one of the GFL (GDNF family ligands) with one coreceptor from GFRal-4
family. This is followed by binding of one of the RET molecules to the above formed GFLGFRa complex and subsequent joining of the other GFRa & RET molecules. Henceforth,
resulting in the activation of RET. Absence of the GFL-GFR complex inhibits the
dimerization of the two RET molecules and its downstream signaling. It has been found that
wild type RET phosphorylation occurs only after being stimulated by its ligands and there is
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an increase in the phosphorylation event with the presence of GFR coreceptors. This event of
dimerization and ligand receptor interaction results in strong control of the cells response to
growth factor.10 Murakami et al (2007) have proposed that GDNF plays a important role in
RET downstream signaling. In their paper they established the fact that GDNF regulates the
downstream signal transduction pathway of RET along with SPHK1 gene.32 The coreceptor
Gfra4 from the GFRa family of receptors has also been reported to play an important role in
activating RET along with GDNF during endocrine cell development.33
The expression of RET is essential for embryonic development, formation of enteric nervous
system and uteric bud development. RET protooncogene has been primarily associated with
Hirschsprung disease (congenital agangliosis of the gastrointestinal tract), thyroid carcinoma,
and Multiple Endocrine Neoplasia 2 (MEN2A, MEN2B) syndromes.7,8 Because of its
importance in various biological processes, scientists have had an increased interest in the
study of the RET proto-oncogene in various research field like tumor biology, neurogenesis,
neuronal disorders, nephrogenesis and reproductive medicine and spermatogenesis.4
RET- Tyrosine kinase domain:

The binding of RET with GDNF and GFRal results in autophosphorylation of RET. The
phosphorylation of RET occurs in its intercellular tyrosine kinase domain. The
autophosphorylated RET forms the docking site for various adaptor proteins which finally
initiates the signaling cascade for the following signaling pathways: RAS/extracellular
signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/AKT, p38 mitogenactivated protein kinase (MAPK) and c-Jun N terminal kinase (JNK) pathways4. After the
activation of RET and its initiation of signaling cascade, RET is ubiqutinated and degraded.
The degradation of RET is mediated by proteosomes5. The two isoforms share 1,063 amino
7

acids but differ at their carboxy-terminal tails. RET9 ends with a 9-amino-acid tail and is
1072 amino acids long, whereas RET51 has 51 different amino acids at its carboxy-terminal
tail with a length of 1114 amino acids. There are total 18 tyrosine residues in the intracellular
domain of RET. Tyr905, Tyrl015, Tyrl062, and Tyrl096 have been found to be of special
significance in RET signaling events. The longer isoform of RET (RET51) contains all the
18 tyrosine residues while the shorter isoform of RET (RET9) lacks the two tyrosines (Tyr
1090 and Tyrl096)11,12. The Tyrl062 of RET forms a docking site for several adaptor
proteins like DOKs, Enigma, She, FRS2 and hence forms an important site in GDNF- RET
signaling pathway. It forms the multidocking site for both the isoforms but shows some
difference in the sequence context. The Tyrl062 has also been seen to play an essential role
for GDNF- mediated neuronal differentiation and signaling. Among the other tyrosine’s of
RET, Tyr 905, Tyrl015 and Tyrl062 undergoes robust phosphorylation with increasing
concentration of GDNF during the embryonic development in DRG (dorsal root ganglion)
neurons.11,12 The Tyrl062 has been found to play an important role in differentiating the
activity of the two isoforms of RET (RET9 and RET51). The structural and functional
difference between RET9 and RET51 results from the alternative modes of binding of
adaptor proteins to the Tyrl062 residue. Mutation of Tyrl062 in RET9 isoform results in the
reduction of its ability to develop the enteric nervous system but doesn’t show any effect on
RET51 activity. Y1096 is essential for the binding of the Grb2 adaptor protein. Jain et al
(2006) have reported that presence of Y 1096 in RET51 helps it to perform its signaling
process even in the absence of Y1062. The adaptor protein, Grb2 helps in coordinating cell
proliferation and differentiation mediated by RET during embryonic development41. Hence,
Wong et al. in 2005 reported that among the two isoforms of the gene RET, RET 9 plays a
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larger role in the development of kidney and enteric nervous system13. Previous research on
this has also indicated that expression of RET9 occurs much earlier during the embryonic
development than RET51. In the case of Hirschsprung disease (HSCR) it has been found that
the people affected by the disease possess undeveloped kidneys. Also the primary cause for
the HSCR disease has been recognized as the missense mutation of RET51 isoform but not
RET914. This report further establishes the fact that the two isoforms RET9 and RET51 vary
in their physiological function and both are required for kidney development, but in different
stages.
RET and diseases:

The gene RET is expressed in the developing kidney, parasympathetic nervous system and
central nervous system nuclei during vertebrate embryogenesis. In the adult tissues RET
expression is seen in the peripheral enteric, sympathetic and sensory neurons plus in neuronal
cells of the brain3. Mutation of the RET gene is responsible for Medullary Endocrine
Neoplasia (MEN2) syndromes, Papillary carcinomas of the thyroid gland (PTC), and
Medullary thyroid carcinoma (MTC).
Mutations in the extracellular domain of the RET gene results in MEN2A while intracellular
domain mutations causes MEN2B. MEN2B mutation results from the change of Methionine
in tyrosine kinase domain of RET. Wild type RET activates with the help of ligands but in
case of MEN2B the replacement of methionine with threonine results in a mutant RET
tyrosine kinase domain which can activate itself without ligand binding15. MEN2A causes
substitution of extracellular cysteine with several other residues (Ex. Arginine). These
cysteines form intramolecular disulfide bonds in the wild type receptor. Due to the
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replacement of cysteine with other residues in the mutant receptor, the cysteine start forming
intermolecular disulfide bonds with another RET-MEN2A monomer resulting in the
activation of RET without any ligand binding.16
A fusion of the RET tyrosine kinase domain with the 5 ’ terminal region of the heterologous
genes results in chimeric oncogenes designated as RET/PTC. To date 12 rearranged forms of
RET have been found. In each case the intercellular domain of RET is fused to different
activating genes namely H4, PCM1, ELKS, RFP. RET, H4, RFG all of which map on the
long arm of chr.10 and their fusion is generated by inversions. In case of RET/PTC2, it
occurs by reciprocal balanced translocation between chromosome 10 and 17 between RET
and RI alpha.17
Hereditary medullary thyroid cancer (MTC) is inherited as an autosomal dominant trait,
which means each child of an affected parent has a 50/50 probability of inheriting the mutant
RET proto-oncogene from the affected parent. DNA analysis makes it possible to identify
children who carry the mutant gene; surgical removal of the thyroid in children who carry the
mutant gene is curative if the entire thyroid gland is removed at an early age, before there is
spread of the tumor.18,19
Hirschsprung’s disease occurs during the fetal development, resulting from the failure in the
development of nerve cells in the enteric nervous system. Absence of these nerve fibers
results in intestinal obstruction, enlargement of the colon and ultimately leads to bowel
obstruction due to the absence of normal enteric nerves of that section. This disease is named
after Harald Hirschsprung who first described the disease in 1886. The disease usually occurs
in infancy. It is multifactorial, involves several genes some of which are still unknown and
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has high sex bias. It has been found that it gets transferred from the male parent to his son in
most of the cases and the reason for that is still unknown.21
RNA splicing:

Splicing refers to a process in which a mature functional mRNA sequence is formed by
cutting and removal of the introns and ligation of the exons24. It has been reported that of the
~25,000 genes encoded by the human genome more than 70% produce transcripts that are
alternatively spliced.51 According to Wang et al. (2008) splicing is essential for removing
introns from nearly 90% of the human gene sequences. They have also reported splicing
defects are responsible for most of the mutations associated with human hereditary
diseases49. It has been also recorded that ~16% of the 31,250 point mutations listed in the data
base of human disease alleles are located within splice sites53. The first chemical step of
splicing includes cleavage of the 5’ exon/intron boundary through nucleophilic attack by the
2’-hydroxyl of a specific branch point adenosine located within the intron. This step results
in the generation of a 5’-exon fragment and a lariat intermediate that contains intron, the 3’exon sequences, and the branched adenosine. The second chemical step is followed by the
cleavage of the 3’-exon/intron boundary through the nucleophilic attack of the 3’-hydroxyl of
the 5’-exon at the 3’-splice site. This step results in the ligation of the exons and the release
of the intron in the form of a lariat50. In the pre-mRNA that undergoes splicing the 5’-splice
site is defined by a single element of 8 nucleotides and the 3’-splice site is defined by three
sequence elements usually contained within 40 nucleotides upstream of the exon/3’-intron
junction52. Human genome mostly contains exons flanked by long introns. According to
Hertel (2007) experimental and computational analysis of the human genome has shown that
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the length of the upstream intron is more important in inducing alternative splicing than the
length of the downstream intron53.
The process of splicing is mediated by the spliceosome machinery, a complex of more than
100 polypeptides and 5 uridine rich small ribonucleoproteins that assembles on the premRNA. UlsnRNP is the first factor to interact with the pre-mRNA and recognizes the 5’
splice site. It form complex with the pre- mRNA and commits the pre-mRNA to the splicing
pathway. Human snRNP is composed of U1 snRNA, SM proteins and U1 specific
polypeptides. Forch et al (2002) reported that apart from UlsnRNP, the protein TIA also
plays an important role in splicing machinery and binds with uridine-rich sequences
downstream from 5’ single strand and promote UlsnRNP binding.47
In many cases, splicing can produce a range of various mRNA by varying the exons of the
same pre-mRNA; this is known as alternative splicing. These mRNAs then undergo
translation and result in the production of different isoforms that differ in their peptide
sequences and thus have varying chemical and biological activity25,26. Alternative splicing
generates protein isoforms that differ in their binding properties to ligands. It causes 2 to 10
fold changes in binding affinity and it further determines the ligand specificity of a
receptor.27 The isoforms generated by alternative splicing in turn lead to the generation of
modified final protein product. Black et al. (2003) have reported that the process of
alternative splicing is attributed mainly to the activities of splicing enhancers and repressors
that further allows transient interactions with splicing regulators.26 Splicing enhancers and
regulators are the cis-acting auxiliary sequences that occur within both exonic and intronic
regions and are responsible for exon inclusion and exon skipping by recruitment or
disruption of the spliceosome machinery.53 Presence of exon splicing enhancers such as SR
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proteins results in the stimulation of spliceosome components such as U2AF. The presence of
splicing silencers such as hnRNP A1 protein results in shifting of splice sites in pre-mRNA.
Similar effects are seen with the presence of intron silencer & enhancer elements like
hexanucleotide UGCAUG and GGGGG. The presence of the above mentioned opposing
regulatory elements in splicing mechanism has resulted in the elaboration of a yang yang
model of alternative splicing. According to this model splicing occurs when positively acting
sites (splicing enhancers) outnumber the negative sites (splicing silencers) 54. The invariable
elements like splice site sequences and exon/intron architecture have also been reported to
possess potential for mediating differential splicing53.

Splicing removes many protein

interaction domains and effects the signaling pathways. Romero et al (2006) reported in their
article that to date 46% of the studied proteins which have alternative splice variants are
involved in signal transduction, gene expression or regulation43.
RET and alternative splicing:

The gene RET has 21 exons and it has been reported to splice alternatively resulting in the
formation of three splicing variants (isoforms); RET9, RET51, and RET43. All these three
isoforms are similar untill the 19th exon and they diverge thereafter6. The isoforms of RET
are well conserved among different species like human, mouse, rat, chicken, and pufferfish.
When the C-termini of RET was compared among different isoforms it was seen that the
amino acids of both the isoforms RET9 and RET51 are similar among all the species
examined. Further comparison of the amino acids both upstream and downstream of the
Y1062 and Y1096 region of the RET protein showed 80% homology among all species22.
Recently, similarity in the expression of RET isoforms has been seen within the neuronal
cells of human and Zebrafish23.
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The loss of one of the isoforms of RET generated by alternative splicing has shown to cause
malformation of kidney and enteric nervous system (ENS) in humans while the loss of the
other isoform of RET did not have any effect in development of both28. The occurrence of
alternative splicing has also been reported in papillary thyroid carcinoma. Fluge et al (2001)
reported the presence of multiple alternative splicing variants of RET-PTC in the genome of
the patients suffering from the disease. They reported the presence of two types of alternative
splicing events in the tyrosine kinase domain of the RET protein, one with exclusion of exon
19 and the other with the retention of intronl9, apart from the usual RET9 and RET51
splicing variants.29 Hir et al. (2000) have reported that RET51 protein isoform has growth
advantage in MEN2 tumors than RET9 protein isoform.

The mutation in RET gene is

responsible for MEN2 syndromes where mutated RET receptor causes alteration of the
downstream signaling and changes the pattern of the target gene expression. Hickey et al
(2009) have described in their article that there is a significant difference in the expression
level of six genes (PIK3CG, RAB3A, INDO, DDX21, CWF19L1, and DSG1) associated
with MEN2 syndrome when induced by either RET9 or RET51. Some of these genes are
either up-regulated or down-regulated by the two isoforms of RET. Gene INDO is of special
importance which is expressed in most human tumor that is induced by RET9 but not by
RET51. Hence, splicing of RET plays a significant role in RET’s regulation and signaling
pattern.20 According to Romero et al (2006) alternative splicing occurs mostly in those
polypeptide segments which are intrinsically disordered. Alternative splicing thus enables
functional and regulatory diversity while avoiding structural complications. They analyzed
46 differentially spliced genes of human proteins and have shown that 81% of them contain
partially or fully disordered protein region.43
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There has been extensive research going on so far with the Isoforms of RET and their
expression. It has been shown that RET gene displays its multiple functions by expressing
various forms of its 3’splicing variants and the aberrant expression of various transcripts may
lead to developmental defects and tumor formation. As demonstrations of the importance of
these splice variations in RET function, RET 9 and RET51 have shown different expression
patterns.6 Previous research in our laboratory has indicated that ligands like glial cell linederived neurotrophic factor (GDNF) plays an important role in the rate of expression of the
isoforms.
In this study, 3 ’ end of the RET 9 isoform and a specific region of the RET gene containing
intronl9-exon20 has been isolated. The region, exon 19 to exon20 has special importance in
the gene RET as this is the region which undergoes differential splicing. There have been
several other research works as well with focus on this region. For example, Jijiwa et al. in
2004 created a construct of genomic RET surrounding the above mentioned regions for their
studies on neuronal cells.30
This study also includes the designing of two genomic DNA constructs of RET by isolating
the 3' genomic DNA sequence of human RET gene with an aim to measure the different
conditions of splice variation and also identify conditions which lead to splicing of human
RET proto-oncogene. The constructs created, also aim to measure the expression of RET 9
and RET51 isoforms using a quantitative QPCR technique. These constructs may play an
important role in further studies related to the event of RET splicing and can be useful to find
the regulator which is responsible for the production of the two isoforms of RET.
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MATERIALS and METHODS
1.

Genomic DNA extraction:

Human genomic DNA was isolated from MCF breast cancer cells using TRIZOL reagent
(TRIzol® Reagent, Invitrogen Life Technologies #15596 USA). 5-10 X 106 MCF cells were
lysed with in 1 ml of Trizol reagent by repetitive pipetting. Then phase separation of the cells
was performed by incubating the homogenized samples for 5 minutes at 15°-30°c followed
by addition of 0.2 ml of Chloroform per 1ml of Trizol reagent. Centrifugation of the sample
at 14,000 rpm for 15 minutes at 2 to 8 °c resulted in the separation of mixture into 3 phases
with the presence of DNA in between the interphase and phenol phase. The DNA was further
precipitated with 300jli1 of 100% ethanol for 30 minutes. This was followed by centrifugation
at 5981 rpm for 5 minutes and a second wash with 75% ethanol. The DNA was ultimately
redissolved with 8mM NaOH after the ethanol was air dried. The pH of the sample was
adjusted as 7.5 with 159 pi 0.1M HEPES and 10 pi of ImM EDTA. The isolated DNA
concentration was measured using NanoDrop™ spectrophotometer (Thermo scientific).
2.

Polymerase Chain Reaction:

The linear genomic DNA sequence of human RET gene was taken from NCBI and EMBL
(NCBI ID No. : AJ243297, EMBL ID No. : ENST00000340058). Exon 19 to exon 20
including introns 19-20 of the human RET gene was targeted for PCR amplification based on
sequence data collected from the above mentioned reference sources. Polymerase chain
reaction was performed with the two sets of designed primers. The first set of primers include
one Forward primer at Intronl8 (5'CACTGTCTCGCTTGGATGAA3') and two Reverse
primers; one at Intronl9 (5'AGGAGGCACTCGTCTGTTGT3') and the other at Exon20
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(5'GCACACACCACAAGGCTCTA3'). These primers were designed to amplify a 2000 bp
and 4000bp regions of the RET genomic DNA respectively. This was followed by the
designing of a new set of primers to amplify a more precise region consisting of a 1910bp
region with the Forward primer at Intronl8 (5'tctcttggagaggtcaggag 3') and reverse primer at
Intron 19 (5’ CACTCGTCTGTTGTCTGAGC 3') around the splicing site. A reverse primer
at Exon 20 (5'TCCCCTTGTGAGTCCATTAC 3') was also designed along with above
mentioned forward primer of the second set to amplify a 900 bp region consisting of the 3 ’
end of the RET9 isoform.
Five different dilutions of the primers were made with concentration of forward and reverse
primers in each 25pl reaction mixture as 0.1pM-0.5pM with 1 pi of DNA and 12.5 pi of
HotStarTaq® PCR master mix (QIAGEN sample and assay Tech.). PCR was performed
using HotStar master mix protocol with 15 minutes at 95 °c for activation, 1 minute at 94°c
for denaturation, 1minute at 53°c for annealing and 3&10 minutes at 72°c as extension for 40
cycles in thermocyler. The amplified product was visualized by running it in 1% agarose gel.
Agarose gel: The amplified DNA was run on 1% agarose gels made with 0.5 g of agarose
per 50 ml of IX TAE. The gels were run in IX TAE with 5 pL of Ethidium bromide (EtBr)
at 100 Volts for 35 minutes.
3.

Ligation of RET DNA into pGEM-T cloning vector:

Ligation: A 10 pi reaction mixture was prepared by adding 1pi of the PCR amplified DNA, 1
pi of PGEM-T easy vector (pGEM®-T Easy vector system from PROMEGA Corp. Cat. No.
A1360), 5 pi of 2X buffer and 1 pi of T4 DNA ligase (INVITROGEN life technologies Cat.
No. 15224-041). The reaction mixtures were kept at room temperature for 1 hour.
17

Transformation: The ligation reaction was centrifuged briefly followed by thawing of the
frozen MAX Efficiency® DH5a™ Competent Cells (INVITROGEN Life technologies Cat.
No. 18258-012). 2 pi of the ligation reaction was added to the 50 pi of the cells. Three such
reaction tubes were made one experimental, positive & negative control and kept in ice for
20 minutes. The tubes were then heat shocked for 45-50 seconds at 42°c water bath and
plated in the LB/Amp plates. The plates were incubated overnight 16 hrs at 37 °c.
Plasmid isolation: Six colonies from the bacterial plates were picked and each was placed in
a test tube containing 10 ml of LB along with 10 pi of 50 mg/ml amp. The bacterial Miniprep
procedure was followed according to the QIAprep® Miniprep protocol (QIAGEN, USA).
The test tube was incubated for 12-16 hrs at 37°c with vigorous shaking (220 rpm). 1.5 ml of
the overnight Bacterial culture from each test tube was taken in a microcentrifuge tube and
spun for 1 minute at 13,000rpm. The pellets were resuspended using 250 pi Buffer PI and
vortexed. 250 pi Buffer P2 were added and mixed well. 350 pi of Buffer N3 was added and
the tubes were again inverted four to six times. The samples were centrifuged for 10 minutes
at 14,000 rpm and the supernatant transferred to a spin column placed in a 2 ml collection
tube. The spin column and collection tube were centrifuged at 14,000 rpm for 30 to 60
seconds and the flow through was discarded. 750pL Buffer PE was added to the spin column
and centrifuged for thirty to sixty seconds and the flow through discarded, centrifuged for
one minute and the collection tube with the flow through discarded. The spin column was
placed in a new 1.5 ml microcentrifuge tube and 50 pi of sterile water was placed in the
center of the spin column. After one minute the column was centrifuged for one minute and
the flow through containing the plasmid DNA was collected.
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Restriction enzyme digestion: The Plasmid DNA was digested with ECOR1. A master mix
was being prepared for 18 reactions containing 20 pi of 10 X buffer, 3 pi of enzyme and 157
pi of sterile water. Each reaction was made with 8 pi of master mix and 2 pi of sterile water.
The 1.5 ml microcentrifuge tubes containing the reactions were kept in the water bath at 37°c
for 4-5 hrs.
DNA sequencing: To further confirm that the amplified region doesn’t contain any mutated
product, the pGEMT-RET insert was sent out for sequencing to an outside lab using SP6 and
T7 universal primers. (GENEWIZ).
4.

Insertion of the approx. 1900 bp amplified region of the RET gene ligated with pGEMT
into mammalian expression vector pFlagCMV-1:

Large scale precipitation of pFLAG-CMV-1:

pFLAG-CMV-1 was first obtained in large

quantity using QIAGEN (QIAprep Spin Midi/Maxiprep Kit) large scale precipitation
,

®

protocol. The pFLAG-CMV-1 DNA was first transformed into MAX Efficiency DH5a
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Competent Cells (INVITROGEN Life technologies Cat. No.18258-012) and a colony was
picked up for the bacterial culture. The 10 ml LB culture containing 10 pi of amp was
incubated at 37 °c for 6-8 hrs. The culture was then picked up and transferred into a 500ml
LB broth with 500 pi of amp for 12-16 hrs. The culture was spun for 10 minutes at 3000rpm
and the pellet was redissolved with 10ml of buffer PL The solution was transferred to a new
tube and 10 ml of P2 was added and mixed vigorously. 10ml of buffer P3 was subsequently
added and centrifuged for 30minutes at 12,000 rpm. The supernatant was then transferred to
a column by passing through two layers of cheese cloth. The column was further washed 2
times with 30 ml of buffer QC and 15 ml of buffer QF was added. The eluted DNA was
further collected in a collecting tube and isopropanol was added and the mixture was
19

centrifuged at 12,000 rpm at 30 minutes. The supernatant was poured out and 5ml of 70%
Ethanol was added to the pellet. The pellet was further washed with 200 pi of EB buffer and
was transferred to an eppendrof tube.
Restriction enzyme digestion: The plasmid p-FLAG-CMVl, pGEMT-RET (the amplified
region of RET ligated with pGEMT) were digested with ECOR1, SAL1 and NOT1 to isolate
the RET construct from the cloning vector pGEMT and further insert it into mammalian
expression vector pFLAG.
DNA purification using column: A large scale prep of the pGEMT-RET plasmid was
performed and the DNA concentration was also determined using (250pg/ml). This time the
two large scale prep plasmid samples were digested using another restriction enzyme NOT1
for 2 hrs and the insert containing plasmid pGEMT was further digested with SAL1 for 3 hrs
to prevent its ligation to itself. The plasmids were re purified using a CENTRE SEP
COLUMNS protocol (PRINCETON Separations Inc. Cat. No. CS-900). The column was
first hydrated by adding 800 pi of water, shaken, vortexed and kept for 30 minutes at room
temperature. After the gel inside the column has settled the air bubble were removed by
tapping the column and the stopper of the column was separated. The excess column fluid
was allowed to drain into a waste tube. The column was spun at 3000 rpm to remove the
interstitial fluid. Approximately 300 pi of the fluid was removed. 20 pi of Dye-Deoxy
terminator reaction mixture was added to the top of the gel followed by careful dispersion of
the sample directly to the center of the gel. The column was placed into a sample collecting
tube and the spun at 3000rpm for 2 minutes. The purified sample was collected in the tube.
Ligation: The purified product was then ligated in different vector: insert ratio (1:3, 1:6, 1:10,
and 1:15) using T4 DNA ligase (PROMEGA Cat. No. M l801) for lhr.
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Transformation of the ligated products: All the ligated products of the above mentioned
.

.

.

.

®

ligation reactions were transformed to 50 pi of one shot MAX Efficiency

DH5a

t m

Competent Cells (INVITROGEN Life technologies Cat. No. 18258-012). The bacterial
transformation reaction were placed on pre-warmed LB/amp plates and grown overnight at
37°c for 16 hours.
Plasmid isolation: 8 colonies from the 2 plates (1:3 and 1:6 ligation reactions) were further
cultured for 16 hrs and the plasmid DNA was isolated by following the QIAprep® Miniprep
protocol.
Restriction digestion: Further digestion with the restriction enzyme NOT1 was performed for
an hour and a 1% agarose gel run.
Orientation confirmation: The two colonies containing the ligated pFLAG vector plus insert
were further digested with the restriction enzyme ECORV.
Confirmation of the ligated product: Both the ligated plasmids were sent for sequencing to
further confirm their orientation. The sequencing was done using CMV forward primer from
GENEWIZ.
Large scale prep of the plasmid -A large scale prep of the new pFLAG-RET was performed
using QIAprep® Maxiprep protocol.
5. Mammalian Cell Transfection

30 pi of lipofectamine was added to 1 ml of serum free media in a microcentrifuge tube. 5 pg
of Plasmid DNA was added to 1ml of serum free media. The two tubes are mixed and
incubated for 10 minutes at room temperature. The Vero cells (cell line derived from kidney
epithelia cells of green monkey) were washed 2 times with 2.5ml of serum free media and
2.4 ml of serum free media was added to the tube. The tube was now added to the plate. The
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plate was incubated for 4-6 hrs at 37°c. The media was removed and the cells are washed 2
times with 2.5 ml media plus serum or IX DPBS. 5 ml of media plus serum was further
added and the cells were incubated for 48-72 hrs.
6.

Isolation of total RNA

After transfection the RNA was extracted from the Vero cells using Absolute RNA Miniprep
kit (STRATEGENE). 4.2pi of (3-ME was added to 1000 pi of lysis buffer. The tissue culture
dish was aspirated and lysis buffer p-ME mixture was added to the dish. The cell lysate was
mixed by repeated pipetting and the lysate was transferred to a microcentrifuge tube. 700 pi
of the homogenate was added to the spin column and spun at 14,000 rpm for 5 minutes. 70%
Ethanol was added to the filtrate and the mixture was filled to rRNA binding spin cup. The
mixture was spun at maximum speed for 30-60 seconds. 600 pi of IX wash buffer was add
and spun for 30-60 seconds. The wash step was repeated twice and 300 pi of IX low-salt
wash buffer was added. The cup was spun for 2 minutes to dry the fibre matrix and then
transferred to a 1.5 ml microcentrifuge tube. 100 pi of warmed elution buffer was added and
the mixture was incubated for 2 minutes at room temperature. The RNA was furthered stored
at -80°c. The concentration of the RNA was measured with 1XTBS in a spectrophotometer.
7.

mRNA isolation

The mRNA was isolated from the total RNA obtained from neuronal cells (SKNSH human
neuroblastoma cell line) using Oligotex mRNA spin-column protocol. The 100 pi of total
RNA (lmg/ml) was pipette into a RNase free microcentrifuge tube and 150 pi of RNase free
water, 250 pi of buffer OBB, 15 pi of Oligotex suspension buffer was added. The sample
was incubated for 3 minutes at 70°c in a water bath. The sample was removed from the water
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bath and kept for 10 minutes at room temperature and centrifuged at 14,000 rpm for 2
minutes. The mRNA pellet was resuspended by adding 400 pi of Buffer OW2 by vortexing
and the mixture was transferred to a spin column. The column was centrifuged and 400 pi of
Buffer OW2 was added to the column and further centrifuged for a minute. 20-100 pi of hot
(70°c) Buffer OEB was added onto the column and the resin was resuspended. The tube was
centrifuged for 1 minute at maximum speed and 100 pi of (70°c) elution buffer was added for
further yield.
8.

RTPCR

cDNA synthesis- The SuperScript™II First Strand Synthesis System for RT-PCR (Invitrogen
Life Technologies Inc.) was used for the reverse transcription reaction following
manufacturer's protocol. The primer pair sets designed for amplifying the RET construct
RNA are as follows: The Forward Primer 5 ’ATGCTATGAGGCTGGCCCGT 3’

was

designed in exonl9 and the reverse primer5’GGCAGTGTAGGGCAACAGCA3’ pair was
designed in intron 19 spanning 175 bp region for amplification of RET9 isoform. The other
set was designed to amplify 150bp region in between exon 19 and exon20 for RET51. It
included forward primer in the exonl9 5'CCCGTGTGCACCCTCGATTT3' and the reverse
primer in the beginning of exon 20 5'GGCAGTGTAGGGCAACAGCA3'.
Intron-spanning primers Intronl9 forward 5' ATGCTATGAGGCTGGCCCGT3' and
Intron 19 reverse 5' GGCAGTGTAGGGCAACAGCA 3' were designed to amplify 160bp
region of intron 19 in human RET.
Two sets of specific exon splice junction primers with the first set containing Forward Primer
5' CTCTATGGCATGTCAGACC 3' in between 7 bases in exon 19 & 12bases in exon 20,
reverse Primer 5' CCCTTGTGAGTCCATTAC 3' with all bases in exon 20 and the second
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set with the Forward Primer 5' AAACTCTATGGCATGTCAG 3' within 10 bases in exon 19
& 9 bases in exon 20 and reverse Primer 5' CCCTTGTGAGTCCATTAC 3' same as above
with all bases in exon 20 were designed.
IOjliI of the sample containing lmg/ml total RNA, lOmM dNTP mix, 2pM gene specific
primer and RNase free water were heated at 65°C for 5 minutes. The samples were then
chilled on ice for I minute. The samples were further mixed with 10 pi of DNA synthesis
Mix (4pl of 5X RT Buffer, 2 pi 50mM MgC12, 2 pi of 0.1M DTT, 1 pi of RNAseOUT ™,
lpl Superscript ™IIIRT. They were incubated at 50°C for 50 minutes followed by a final
incubation at 85°C for 5 minutes.
The cDNA prepared from the previous step was amplified using the above mentioned gene
specific primers with HotStarTaq® PCR master mix protocol (QIAGEN sample and assay
Tech.).
9.

Quantitative Real time Polymerase chain reaction

For quantitative real-time polymerase chain reaction (qPCR) experiments the SYBER green
Expression Assays (STRATEGENE) were used. The qPCR analyses was performed by using
an MAXPRO 3000 sequence detection system (STRATEGENE).The qPCR reaction mixture
consisted of DNA diluted 10 fold from the reverse transcriptase reaction (lpl), forward and
reverse primers (1 pi 0.5 pM) with 2X SYBER Green Master M ix (1 2.5 pi) in a final
volume of 25 p i . The qRT-PCR was performed in triplicate for each cDNA sample.
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RESULTS
1.

Isolation of 3’ end of the RET gene

In order to isolate the 3 ’ end of the RET gene for future splicing studies, genomic DNA was
isolated from MCF-7 cells, a human breast cancer cell line. Using 5x 106 cells, 213ng/pl of
genomic DNA was isolated. Polymerase chain reaction was performed with the isolated
DNA & designed primers, to amplify 3’ end of the RET gene. The failure of the
amplification was attributed to the low concentration of the genomic DNA extracted from
human MCF cells. Thus lOOjig of Human Genomic DNA was obtained from Promega and
was used to amplify 1910bp in between intronl8-exon20 & 1289bp in between intronl8intronl9. The first pair of primers was used to amplify the region in between the two exons;
exon 19 and exon20 where splicing of the RET gene takes place and the two isoforms RET9
and RET51 are formed. 1289bp region amplified with the second pair of primers included the
end portion of the 3’ carboxy tail region of the RET9 isoform which contains the last exon
(exon 19) and few bases of intronl9. The polymerase chain reaction was performed with 5
different concentrations (0.1pM-0.5 pM) of the two set of primers. The first five lanes
represent (1900 bp) amplified region with 5 different concentration of the first set of primers.
The 6th-8th lane represent (1200bp) amplified region with 5 different concentrations of the
second set of primers.
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Figure 1: G el show ing

both

1910bp and

12S9bp region o f RET DMA am plified w ith different

con cen tration grad ie n t of prim ers

The 1910 bp region was chosen for further experiments as it includes the specific region
exonl9 and exon 20 where splicing event of RET proto-oncogene occurs.

Exonl9

lntron!9

Exon20

Figure 2: A schematic diagram of the splicing region of the RET transcript. Arrows denote primers
used to amplify the region.
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2.

Cloning of RET insert into pGEM-T vector

The RET (1910 bp) DNA from the previous PCR reaction was ligated to the pGEM-T
cloning vector. This vector was used for its cloning efficiency and its characteristic 3'
thymidine-overhang which easily ligate (without the use of ligase) with the deoxyadenosine
overhang that Taq polymerase leaves in PCR products. A positive and a negative control
were also made by adding a control insert DNA in case of positive control and only water in
negative control. After ligation, the vector containing 1910bp insert of human RET DNA was
transformed into 50 pi of competent DH5- a bacterial cells. The transformed cells were
plated onto pre-warmed LB-Ampicillin plates and grown overnight. 16 colonies grew, 8 of
which were later cultured in LB/amp broth overnight for miniprep. The excised DNA
samples of the miniprep were then restriction digested with ECOR1 and showed the presence
of approx. 2kb insert with the 3kb pGEMT plasmid vector when run on a 1% agarose gel.
Thus a new plasmid containing the foreign DNA (as an insert) was assumed to have been
obtained.
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The automated sequencing data thus obtained had 99% similarity with human RET genomic
sequence (exon 19-20) when a blast search was done using NCBI database.
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NCBI Blast result of pGEMT- RET sequenced with Forward SP6 primer>ref|NG 007489.1 i HI Homo sapiens ret proto-oncogene (RET) on chromosome 10
Length=c0283
Score = 1729 bits <936), Expect = 0.0
Identities = 941/943 (99%), Gaps = 2/943

(0%)

Sfc r a s d = P l u s / P l u s

Query

3

AGCC~GAGCCTCTGCCCTGAGGA-GGCTTGTTGTATACTGAGT1G:IATCTAGTTSTGGCA

65

Sb j ct

54411

AGCCAGAGCCTCTGCCCTGAGGATGGCTTGTTGTATACTGAGTTGTATCTAGTTGTSGCA

54470

iin

m ii

1 1 1 it i n 1 1 i n

i!m i m

i ; 11 m i i m m i m

im i m

Query

€€

CATGGCTfGGAGTGACCGGCCATCTCTGTCTTCCAGGACTACTIGGACCTxGCGGCGTCC

125

Sbjct

54471

eATGGCTXGGAGTGACCGGCCATCTCTGTCTTCCAGGACTACTTGGACCTTGCGGCGICC

54530

Query

126

ACTCCATCTGACTCCCTGATTTATGACGACGGCCTCTCAGAGGAGGAGACACCGCTGGTG

185

m 11 m 1 1 1 m m m i m

Mi i i n I m i m

m

m n

m

111 m m i n m i m i m i i t m i m i m

11111

m m

im

11 m m i m

m m m

m im

Sbjct

5 4 .5 3 1

ACTCCATCTGACTCCCTGATTTATGACGACGGCCTCTCAGAGGAGGAGACACCGCTGGTG

54590

Query

18c

GACTGTAATAATGCGCCCCTCCCTCGAGCCCTCCCTTCCACATGGATTGAAAACAAACTC

245

Sbjct

54591

GACTGTAATAATGCCCCCCTCCCTCGAGCCCTCCCTTCCACATGGATTGAAAACAAACTC

Query

24c

TATGGTAGAATTTCCCATGCATTTACTAGATTCTAGCACCGCTGTCCCCTCTSCACiATC

Sb jct

54651

TATGGTAGAATTTCCCATGCATTTACTAGATTCTAGCACCGCTGTCCCCTCTGCACfATC

54710

Query

365

m m

II

m

n in m

m m

i m iin im m

1111 m m n i i n

m

m m i m 1 1 iin n m n n m i m i n m m m

m m m m

11 m 1 1 i i i i n

54650
305

3 06

CTTCCTCTCTGTGAT&GTfTTTAAAAATGTTTCTGGTCTGAACAAAACCAAAGTCTGCTC

Sb j ct

54711

CTTCCTCfdGTGATGCTTTTTAAAAAIGTTTCTGGTCTGAACAAAACCAAAGTCTGCTC

54770

Query

366

TGAACCTTTTTATTTGTAAATGTCTSACTrTGCATCCAGTTTACATTTAGGCATTATTGC

425

Sbjct

54771

TGAACCTTTXTATTTGTAAATGTCTGACTTTGCATCCAGTTTACATTTAGGCATTATTGC

54830

Query

42€

AACTATGTTITTCTAAAAGGAAGTGAAAATAAGTGTAATIACCACATTGCCCAGCAACTT

485

Sb j ct

54831

AACTATGTTTTTCTAAAAGGAAGTGAAAATAAGTGTAATTACCACATTGCCCAGCAACTT

54890
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Query

486

AGGAIGG” A.GAGGAAAAAACAGATCAGG'GCGGAACTCICAGGGGAGACCAAGAACAGGIT

545

Sbj ct

54891

AGGATGGTAGAGGAAAAAACAGATCAGGGCGGAACTCTCAGGGGAGACCAAGAACAGGTT

54950

Query

546

GAATAAGGCGCTTCTGGGGTGGSAATCAAGTCATAG7ACTTCTACTTTAACTAAGTGGA7

605

Sbj ct

5 e * 31

GAATAAGSCGCTTCTGGGGTSGSAATCAAGTCATAGTACTTCTACTTTAACTAAGTGGAT

55010

Query

606

AAATATACAAATCTGGGGAGSTAXTCAGTTGAGAAAGGAGCCACCAGCACCACTCAGCCT

665

Sbj ct

55011

AAATATACAAATCTGGGGAGGTATTCAGTTGAGAAAGGAGCCACCAGCACCACTCAGCCT

55070

Query

666

GCACTGGGAGCACAGCCAGGTTCCCCCAGACCCC'ICCTGGGCAGGCAGGTGCCTCTCAGA

725

Sbj ct

55071

GCACTGGGAGCACAGCCASGTTCCCCCAGACCCCfCCTGGGCAGGCAGGTGCCT CTCAGA

55130

Query

726

GGCCACCCGSCACTGGCGAGCAGCCACTGGCCAAGCCTCAGCCCCAGTCCCAGCCACATG

785

Sbj ct

55131

GGCCACCCGGCACTSGCGAGCAGCCACTGGCCAAGCCrCAGCCCCAGTCCCAGCCACATG

55190

Query

786

TCCTCCAICAGGGGTAGCGAGGTTGCAGGAGCTGGCTGGCCCTGGGAGSACGCACCCCCA

845

Sbj ct

55191

TCCTCCAICAGGGGTAGCGAGGITGCAGGAGCTGGCTGGCCCTGGGAGGACGCACCCCCA

55250

Query

846

CTGCTGTfTXCACATCCTTTCCCTTACCCACCTT€A.GGACGGTTGTCA.CTfAIGAAGTCA

905

55251

CTGCTGTTTTCACATCCTTTCCCTTACCCACCTTCAGGACGGTTGTCACTTA1GAAGTCA

55310

Sbjct
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NCBI Blast result of pGEMT- RET sequenced with Reverse T7 primer
>refjNG 0 0 7 4 8 9 . 1 | S 8 Homo sapiens ret proto-oncogene (RET) on chromosome 10
Length=T028 3
Score - 1707 bits {924}, Expect = 0.0
Identities = 944/552 (99%), Gaps = 7/952 (0%)
Stran 3=51u a/Mi nus
Query

4

AC7ATC-AACGTGGTCCATTAA.TTTTGCCGCXGAGGGTGAAAGCAECCAGT7AGCAXATA

62

Shi ct

56193

ACTATCA&ACGT-GTCCATTAATTYTGCCGCTGAGGGTGAAAGCATCCAGTTAGCATATA

56I4?3

Query

€3

CACTATCATTTGGATATCTTGGAAACCCAGTGTTAGTGCCATCAGCTCTCGTGAGTGGTA

122

Shi ct

56139

CACTATCATTTGGATATCTTGGAAACCCASTGTTAGTGCCATCAGCTCTCGTGAGTGGTA

56080

Query

123

CAGGACTCTCTCCAGGCCAGTTCGGGTCTGACAXGCCTAA&AATGAAAACAGATCATTTG

182

Sb jct

56079

CAGGACTCTCTCCASSCCAGTTCGGGTCTGACAXSCCTAAAAATGAAAACAGATCATTTG

Query

133

TXCTGCACTGAAGAACCAAAACTTCAAGTGCASACAGTAAGGCCTTGGGAAAACTCCCTT

Sb 1ct

56019

XTCSGCACTGAAGAACCAAAACSTCAAGTGCAGACAGTAAGGCCXTGGCAAAACSCCCTT

24
55960

Query

243

TGAXGTTCAAACCAAACTCGTGGTTTCTGTGCCAATTATATXAAXGGTTTTGTGXXCCAG

302

Sbjct

55959

TGATGTTCAAACGAAACTCGXGGTTTCTGTGCCAATTATATTAATGGTXTTGTGTTCCAG

55900

Query

303

GTTTCCAAAAACACT5TTATAGTTAGGGGAAATASCATGXGCTC2CTTGGXAAASGTAAC

362

Sbjct

55399

GTTTCCAAAAACACXGTTATAGTXASGGGAAATAXCATGTGCTCXCTTGGTAAAXGXAAC

55840

Query

363

TTAACAGAGACTACCAATTTTGACXTTTATGAACTTGAGACSCXCTAATCTGAXGTATAT

422

Sbj ct

55339

TTAACAGACACTACCAATTTTGACXTTTATGAACXTGAGACTCTCXAATCTGATSXATAT

55780

Query

423

STGXCGAACTGC'XTAACTCTTXTXCXAAGGCAGXGTAGGGCAACAGCACACXGCXGCACT

432

Shi ct

55773

XTGTCGAACTGCTTAACXCTTTTTCTAAGGCAGTGTAGGGCAACAGCACACTGCTGCACT

55720

Query

433

CAAXSGCTTACTGCA5CGGAAACGXTCTATAAAACATTCTCTAAC5TAAAGGAGGCACIC

542
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56020

Sb jct

55719

CAATG5CTTACTGCAGCGGAAACGTTCTATAAAACATTCTCTAACGXAAAGGAG6CACTC

55660

Query

543

GTCXGTTGTCTGAGCCTACAACGGAGAAGAGGACCXTCCAAATCGAGGGTGCACACGGGC

602

Sbjct

55659

GTCTGITGTCTGAGCCTACAACGGAGAAGAGGACCTTCCAAATCGAGGGTGGACACGGGC

55600

Query

€03

CAGGCTCATAGCATCGTCAGCACAAAXGGAGTGTGGCACTAGACACAAAGCCAGTGAGGA

662

II m n i i n n m

1111 m s i m i n n n m i m 11 m m i m 111 m

I H I m I I H I I I 1 H I I I 11 I 1 I 1 I I 1 S H I I 1 I H I I H I I 1 1 H i I I H I I 111 H

Shi ct

55599

CAGCCTCATAGCATCGTCAGCACAAATGGAGTGTGGCACTAGACACAAAGCCAGTGAGGA

55540

Query

663

GTCAGTGAGTCAGGAGGCATGCAAAAGGAACCGTCTCAGCTTGaaaaaaaTGCXTGAAAC

72?

Shi ct

55539

GTCAGTGAGTCAGGAGGCATGCAAAAGGAACCGTCTCAGCTTGAAAAA&ATGGTYGAAAC

55480

Query

723

XCCAAGATTTCAAACAATCAATGATGAAGTTAGGAAACAGJiAAAAATTTCTAGTATTTAA

782

Sbjct

55479

XCCAAGATTTCAAACAATCAAXGAXGAAGXTAGGAAACAGAAAAAATTTCTAGTATXTAA

55420

Query

733

TCGAAGACAAAAGAAGGAGTTTXGGCAAGAACCATAXTTACTGTCCATTGTAAGACCACA

842

Sbjct

55419

TCAAAGACAAAAGAAGGAGTTTTGGCAAGAACCATATTTACTGTCCATTGTAAGACCACA

55360

Query

843

GCACCACAGACCAXGTTCTTXCAAAAAGCAACTGCTCCAGCXTTASCACTGACTXCAXAA

902
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Sequences producing significant alignments:
Max
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Homo sapiens ret proto-oncogene (RET), transcript variant

1
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A large scale prep of the cloning vector pGEMT containing the insert was performed to
generate it in large amounts and make it more purified. Its DNA concentration (250pg/ml)
and A260/A280 ratio of 0.099/0.062=1.6 were also determined.
3.

Creation of RET-pFLAG-CMV-1 constructs-

To express the amplified product into mammalian cells it is necessary to insert it into a
mammalian expression vector. pFLAG-CMV-2 was chosen for the purpose as it is a shuttle
vector for E. coli and mammalian cells of 4.7 kb in size, used for expression and secretion of
N-terminal FLAG® fusion proteins in the mammalian cells. The promoter-regulatory region
of the human cytomegalovirus2 drives transcription of FLAG-fusion constructs. It also
results in most efficient replication in Vero cells. A large scale prep of the pFlag plasmid was
performed and its concentration (375pg/ml) was measured by a spectrophotometer using
A260/A280 ratio as 0.15/.082= 1.8.
Three common restriction digestion sites (ECOR1, ECORV, NOT1 and SAL1) between the
two vectors, pFLAG and pGEMT were determined in such a way that they are not common
with the restriction sites present within the insert using NEB cutters from Biolabs. The aim
was to cut the insert from pGEMT vector and ligate it with pFLAG-CMV-1. Different
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methods such as In-gel ligation, Ethanol precipitation, Addition of ECOR1 site to the insert
DNA, purification using column was performed. In case of in gel ligation the ECOR1 &
SAL1 digested plasmids were precipitated using ethanol and sodium acetate and further
ligated using T4DNA ligase for an hour using 1:3 vector to insert ratio. The insert was again
amplified from the cloning vector pGEMT by adding ECOR1 sites. The PCR amplified insert
with added ECOR1 restriction site was run in a 0.8% agarose gel and it was extracted. Then
it was ligated with ECOR1 digested pFLAG vector. And finally success was achieved using
column purification and NOT1 and SAL1 restriction enzymes. The plasmids were both
double-digested with NOT1& SAL1 and single digested with SAL1 for an hour. The
digested regions of the pFLAG plasmid and the 1910bp insert were then visualized by
running on a gel. The digested products were further purified using purification columns
from Sigma. The purified product was then ligated in different vector: insert ratio (1:3, 1:6,
1:10, and 1:15) using T4 DNA ligase for lhr. The ligated products were plated into LB/amp
plates and 50, 50, 100 colonies were obtained after an overnight incubation at 37°c. The
earlier ligation reactions had not shown any colonies except the last one which formed
colonies at different vector to insert ratio ligation ranging from approx.50-500.
8 colonies were picked from the plates and Miniprep was performed. The plasmid Miniprep
samples were further digested with Notl and Sail restriction enzymes. After running on a
1% agarose gel two samples were assumed to have the ligated vector plus insert.
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These two samples were further digested with ECORV; which cuts the insert at its extreme
end and the vector just before its multicloning site to confirm their orientations. One with
almost 2kb insert and approx. 5 kb vector proving its anticipated forward orientation and the
other with approx 6 kb fragment and approx.200 bp fragment indicating its inverted
orientation were obtained.

pFLAG-CMY-1 vector 4 7Kb after ECOR5 dip«
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Figure 8: The map showing the Forward
orientation of the amplified product
inside pFlagCMV-1 gene.

Map 2

Figure 9: The map showing the reverse
orientation of the amplified product
inside pFlagCMV-1 gene.

The samples were sent for sequencing at GENEWIZ to further confirm their orientation and
presence of insert. The sequencing result confirmed the presence of the insert (RET) ligated
with pFLAG. A large scale prep of the new pFLAG-RET was performed to purify it so that it
can be transfected into mammalian cells.
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NCBI Blast showing RET construct with forward orientation within pFLAG-CMV vector
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NCBI Blast data showing the RET construct with reverse orientation within pFlag-CMV
vector
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RNA analysis-

The purified pFLAG-RET constructs both forward and reverse orientation of 797pg/ml
(reverse) and 1087 pg/ml(forward) were transfected into Vero cells. The total RNA was
extracted and the primers were designed to amplify RET9 and RET51 RNA.
To be used as a positive control, RNA (RAGD72 lmg/ml) from neuronal cells were used.
The first set of primer pairs designed to amplify RET9 and RET51 were tested with this
RNA. The graph below represents the quantitative expression of RET isoforms in neuronal
RNA with Invitrogen superscript reverse transcriptase - cDNA and SYBR real time per
reagent. The following graph shows the expression of RET9 and RET51 with and without
reverse transcriptase. The dark bars represent the ct value obtained from cDNA without
reverse transcriptase and the light bars are for ct values with reverse transcriptase. The first
pair of bars represent the control ct value obtained with 18s universal primers. In real time
PCR data, lower the number of cycle higher is the expression level of RNA. Thus, it shows
that in case of neuronal RNA, the RET9 isoform is expressed in higher level than RET51.
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Serial dilutions of the positive control RNA were performed to obtain a standard curve for
the quantitative PCR, using RET51 primers and neuronal RNA. The graph below represents
the expression of the RET51 RNA obtained from 5 fold serial dilution of the cDNA obtained
with Invitrogen superscript!! cDNA synthesis kit.
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Standard Curve

Dilutions

The table below represents the concentration of the dilution series. Dilution was made using
a 1:5 ratio of the template cDNA and DI water.

Dilutions
0.2
0.04
0.008
0.0016
0.00032

ct
Value
19.32
21.75
22.46
22.65
22.75

The RNA specific primers for meant to amplify RET51 mRNA was further were further used
to amplify the construct RNA (total RNA obtained by inserting the constructs into the Vero
cells). The amplified product from the RT PCR reaction was sent for sequencing.
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Sequencing data from GENEWIZ of RET mRNA amplified with RET51 forward primers
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Sequencing data from GENEWIZ of RET mRNA amplified with RET51 reverse primers
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The sequencing result showed the presence of introns in the amplified region and the
amplified region was 1500bp long containing exon 19 and intronl9. The same reaction was
performed with the neuronal RNA and a similar result was obtained. A new primer set was
designed to verify the presence of unspliced RNA product in the neuronal cells RNA and the
mRNA was purified from the total RNA. A new transfection with the purified pFLAG-RET
constructs both forward and reverse orientation of 797pg/ml (reverse) and 1087
pg/ml(forward) was further transfected into Vero cells.
The amplification of the construct RNA, neuronal RNA obtained from SK-N-SH cells,
mRNA (extracted from neuronal RNA) with all the different sets of primers showed the
presence of two bands in 1% agarose gel. The size of the bands was approx 1500 bp and 150
bp respectively.

Figure 12: mRNA amplification of the construct using RT
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Amplification of neuronal RNÀ and RET RNA with RNA primers
!>P
-cRKÂ
-RT

-P
+P
-cRKA -f-cSNA -tRNA -tRKA
-RT
-RT
-RT
-RT

+p
-îRNA
-RT

Í

Primer 1

Primer 2

Figure 13: Amplification of
mRNA using two sets of
exon splice junction
primers and construct RET
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DISCUSSION
Alternative splicing in the gene RET has resulted in the formation of its two isoforms; RET9
and RET51. These two isoforms are expressed differentially in mammalian cells and they
perform important roles in the development of kidney and enteric nervous system. They
differ in their carboxy- terminal tails with respect to the number of amino acids. This
difference has in turn resulted in the difference of signaling properties in between the two
isoforms.13 The ligand GDNF also plays an important role in RET signaling along with the
coreceptor GFRal.

The aim of this research is to investigate the alternative splicing

mechanism in RET protooncogene. Alternative splicing has been associated with various
diseases like cystic fibrosis, muscular atrophy, Parkinson’s disease including various forms
of cancer. There are many examples with transmembrane proteins where among the splice
variants generated by alternative splicing, one form is up- regulated in cancer than the other
ones . The protein RET is a transmembrane receptor protein and is essential for transmitting
growth signals from the extracellular matrix. The diseases like thyroid cancer, MEN2
syndromes, Hirschsprung’s disease has been associated with the RET protooncogene. Recent
studies have indicated that the two isoforms of RET have their individual physiological
function in signal transduction pathways mediated by the gene RET. It has also been
indicated that there may be certain connections between the expression of these two isoforms
and MEN2 syndromes.40 To investigated further on the splicing mechanism of the gene RET,
it thus becomes necessary to design a constmct of the RET proto-oncogene which contains
the specific region where splicing event takes place in a RET gene.
In this study a construct of RET proto-oncogene consisting of the region specific for splicing
event of RET proto-oncogene was constructed. The created construct has approx. 2000 bp of
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RET gene starting from the last 132bp of intronl8 and ends in the open reading frame (amino
acid encoding region) of exon20. This region constitutes of exactly 1910 base pairs. The
splicing event of RET occurs in this region for its two isoforms. The RET9 mRNA contains
the 152 base pair long exonl9 and about 780bp of intronl9 (NCBI ref. No. NM 020630). It
has an open reading frame until 32bp of intronl9. RET 51 mRNA contains both exonl9 and
exon20 (NCBI ref. No. NM_020975) and has an open reading frame until - 258bp in exon20.
The primers were designed to amplify these regions for the creation of the construct. The
amplified region had both exon 19 and intronl9 which forms the end portion of the 9 amino
acid tail of RET9 isoform. Human exonl9 is 152 bp long and has Y1062 which is the last
common tyrosine residue among all the 3 isoforms of RET (RET9, RET51 and RET43).
Y1062 is also located in the end part of this exon. Carter et al (2000) have reported that
Y1062 lies directly upstream of the splice donor site of the exonl9.22 The amplified region
also contained the open reading frame of exon20 which also included the two tyrosines
Y 1090 and Y 1096.
The 1910 base pairs amplified region of RET was further inserted in the mammalian
expression vector pFLAG to ease its mRNA expression in mammalian cells. During the
creation of pFLAG RET construct, two plasmids (one with forward and other with reverse
orientation of RET) were seen in the agarose gel and confirmed by sequencing. These two
forward and reverse orientation constructs were further transfected into Vero cells. It was
expected that the spliceosome machinery would not act on the construct with reverse
orientation and there would be no splicing event. Pasman et al (1996) has shown that the
spliceosome machinery works as a three dimensional diffusion model where functional
interaction between complexes (assembled independently at splice sites) occurs irrespective
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of the presence of introns between them.36 Even if the splicing event occurs, the correct order
of the exons and introns will not be maintained in the two isoforms of RET generated by the
reverse construct. Vanacova et al. (2005) had used reverse orientation of the insert as
negative control in their research involving the role of introns in splicing mechanism.35
The Vero cell line used was initiated from the kidney of the African green monkey and was
expected to express the insert RET efficiently after transfection. The real time quantitative
PCR (Q-PCR) was chosen for validating the mechanism of splicing and formation of two
isoforms RET9 and RET51 in the construct. Real time PCR refers to a process through
which the amplification of products are directly monitored in each amplification cycle.37
The quantification of mRNA can be efficiently performed by using inexpensive DNA
binding dye such as SYBR Green 1 which can be used in real time PCR assays without
individual probe design and optimization. The dye emits fluorescence when bound to the
dsDNA in a sequence independent manner. Thus representing fluorescence intensities
proportional to DNA concentrations.37 To perform the Q-PCR and validate splicing event,
primers were designed in the intron-exon boundaries of RET construct. A primer set
spanning intronl9 was also designed to avoid the potential signals from genomic DNA
contamination and determining unspliced RET gene. The splice site specific primers were
expected to allow differentiation of the alternatively spliced regions of the RET construct.
To design a positive control probe for the constructs, initially the real time PCR was
performed with the cDNA from neuronal cells mRNA that expresses RET. The primers
designed for both RET9 and RET51 were tested on this cDNA and the amplification plots
were noted. The experiment was repeated multiple times using different reverse transcriptase
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kits for cDNA preparation. The same SYBR green kit was used every time to validate the
similar amplification plots in Strategene MaxPro 3000 machine.
A standard curve with cDNA from neuronal cells and the designed primers was made. The
standard curve was generated from (5 fold) serial dilutions of the neuronal cDNA. The
relative concentrations were expressed in arbitrary units and the logarithms of concentrations
were plotted against cross points. The least square fit was calculated and used as standard
curve.38 A standard curve is required for accurate quantification of gene expression levels.
The data obtained from standard curve can be used to compare the abundance of the known
RET9 and RET51 isoforms in the neuronal cells with the unknown quantity of the isoforms
from the mRNA of the generated construct.
The primers were then used to amplify the RNA obtained from transfection of the constructs
into Vero cells. The reverse transcriptase PCR of the total RNA extracted from Vero cells
was sent for sequencing. The sequencing result showed that the RNA contained approx. 1000
bp of RET RNA which included the exon 19, intronl9 and the beginning of exon20; instead
of the 150bp region of spliced exon 19 and exon20. To further investigate the unexpected
result; again three exon splice junction specific primers were designed. Futcher et al have
reported that the study of splicing event generated by genes which posses isoforms that retain
introns are complicated because RT-PCR performed to amplify mRNA with retained introns,
can amplify genomic DNA instead. They also reported that if a gene has an antisense
transcript, that will never be spliced and will yield the same product as an unspliced sense
transcript.41 Until now there has been no report of the presence of antisense transcript in
RET; hence 1500bp region amplified by the RT PCR may have occurred due to the presence
of genomic DNA in the extracted RNA of the constructs. mRNA was further purified from
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the extracted total RNA of the construct but due to low concentration of the obtained mRNA,
the result was obscure. Hence, further purification of the RNA is required to confirm
occurrence of the splicing event in the created construct.
Earlier studies with splicing of different genes have indicated that a gene’s promoter region
(especially the region that regulates gene expression) can also regulate splicing. Hence
splicing can depend on the transcription factor that is bound to the promoter. Futcher et al in
their review article has reported that even though splicing can be mediated by signals inside
the transcript which undergoes splicing, there can be outer signals too which induces splicing
mechanism in certain genes.42 The created constructs can thus be used to study whether the
ligand GDNF plays an important role in the splicing mechanism of RET. Apart from
different regulators of the splicing machinery; the extracellular signaling from factors such as
ligands has been reported to play important role in the splicing events of genes.26 Takahashi
in 2001 also reported the importance of GDNF in RET signaling and their prevalence in
diseases like MEN2A/ FMTC and HSCR.19
The construct can further be used to reveal the factor/ factors which direct the formation of
the RET9 and RET51 isoforms in the spliceosome machinery. Similar work has been
performed with other genes and one of them is by Bonnal et al. with Fas receptors. Bonnal et
al. in 2008 identified the presence of a factor RBM5 which act as a regulator of alternative
splicing event in apoptosis inducing Fas receptors that have 8 known splicing variants. The
presence of splicing signals has also been reported in the introns themselves such as 5’GT
rich signals. These type of spliciosomal snRNP specific splicing signals has been invariably
reported in eukaryotes and are highly conserved among deep-branching lineages.35
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Park et al. (2004) has performed RNAi screening to identify the splice regulatory proteins in
3 alternatively spliced genes of Drosophila. According to them the typical process of
identifying splicing regulators of an alternatively spliced gene starts with construction of a
minigene that accurately undergoes splicing in vitro. The second step requires identification
of RNA sequences required for regulation and finally leading to the identification of proteins
that bind to these elements.44 Hence the constructs of RET gene designed in this study will
serve as the first step in the identification process of splice regulators of the RET proto
oncogene.
The real time PCR data with neuronal RNA has revealed that RET9 isoform is expressed in
higher amounts than RET51. The constructs can also be used to evaluate the increase in
production of RET9 over RET51 mRNA and further during the formation of RET protein
any reversible changes in the amounts of the two isoforms can also be evaluated. The
construct created can thus be used to quantify the fold of increase in the amounts of the two
isoforms.
Ohno et al (2007) developed a transgenic alternatively splicing reporter system to identify the
switch that regulates the expression of two isoform of let-2 gene that encodes collagen in C.
elegans. This gene has two isoforms and they vary in their expression level during the
developmental stages of the nematodes. One isoform is expressed in higher amounts in larval
stage while the expression of another one is higher in the adult stage of the nematode. The
expression pattern of this gene is similar to RET proto-oncogene in which the RET9 is
expressed in higher amount in earlier stages of kidney development while RET51 is required
in later stages and shows higher expression in protein level than RET 9 protein. The isoforms
of the let-2 also differs in between its two exons- exon9 and exonlO similar to exonl9 and
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exon 20 in case of RET proto-oncogene. By using GFP based reporter system they have
identified a novel member of the highly conserved STAR (signal transduction activators of
RNA) family RNA-binding proteins, ASD-2 (for Alternative Splicing Defective-2), as a
regulator of the let-2 alternative splicing.48
The sequencing data of the construct can be used to locate the transcriptional factor binding
site, exon/intron border consensus sequences, exon splicing enhancers (ESE) sequences
which are binding sites for specific serine/Arginine-rich (SR) proteins involved in the
splicing machinery. Cebrain et al. 2005 have used PuPa SNP finder, a web based tool to find
SNP in RET proto-oncogene. The tool also locates the above mentioned regions which are
essential to understand the splicing event of a gene.45 According to Ni et al. (2007)
identification of SR proteins and hnRNPs are essential to understand the alternative splicing
event in any gene.46
In conclusion this study has been able to take the first few steps towards the goal of finding
the regulator which is responsible for the splicing of the gene RET. Our immediate aim is to
use the construct developed in this study to transfect in vitro along with the ligand GDNF and
GFRal and quantify the expression of the two isoforms of RET; RET9 and RET51. The
construct is also planned to be used along with reporter genes to find the switch responsible
for the splicing of the gene RET.
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